An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial
Crossref DOI link:
Published Online: 2016-02-02
Published Print: 2015-12
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Chaker, A. M.
Funding for this research was provided by:
This study was a sponsored clinical trial and funded by Allergopharma GmbH & Co. KG (Reinbek, Germany).